文献速递功能神经外科神经重症

反应性神经刺激联合切除或消融治疗癫痫的多中心经验

Combining responsive neurostimulation with resection or ablation for treatment of epilepsy: a multicenter experience.
PubMed 文献 · J Neurosurg · 2026-10-16

这项多中心回顾性研究纳入9个癫痫中心73例药物难治性癫痫患者,评估反应性神经刺激(RNS)联合切除或激光间质热疗(LITT)的临床决策、癫痫结局与安全性。1年时局灶性意识受损发作平均减少69%,48%患者至少6个月无发作,79%患者整体临床显著改善,3例感染、1例非手术相关死亡。联合策略可能为复杂药物难治性癫痫提供有意义的发作控制且安全性可接受。

要点

  • RNS联合切除或LITT多用于 eloquent cortex 受累(67%)或多灶起源(33%)患者。
  • 1年时局灶性意识受损发作平均减少69%,48%患者至少6个月无发作。
  • 79%患者整体临床显著改善,3例感染、1例非手术相关死亡。

核心结论

  • RNS联合切除或消融可能为复杂药物难治性癫痫提供有意义的发作控制,安全性可接受。

研究设计与样本

  • 多中心回顾性研究,纳入9个癫痫中心73例药物难治性癫痫患者,均接受RNS联合切除或LITT且随访≥1年。

主要发现

  • 1年时局灶性意识受损发作平均减少69%,局灶性发作减少53%,局灶继发双侧强直阵挛发作减少67%。
  • 48%患者至少6个月无发作,4例术后无发作,79%患者整体临床显著改善。
  • 3例感染,1例死于与手术无关的原因(癫痫猝死)。

关键数值与推荐

  • 联合指征包括 eloquent cortex 受累67%、多灶起源33%或两者兼有9.6%。
  • 89%患者同日手术,RNS与切除同步92%、与LITT同步8.2%。
  • 新皮层和内侧颞区占切除/消融靶点61%;超过三分之二RNS电极是硬膜下条片,最常见于左半球73%。

临床怎么用

  • 对 eloquent cortex 受累或多灶起源的药物难治性癫痫,可考虑RNS联合切除或LITT的杂交策略。

局限性

  • 回顾性设计,样本量有限(73例),随访仅1年,缺乏对照,不能明确联合策略的优越性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite advances in surgical and neuromodulatory treatments, a substantial proportion of patients with drug-resistant epilepsy remain ineligible for standalone resection or ablation. Combining resection or laser interstitial thermal therapy (LITT) with responsive neurostimulation (RNS) has emerged as a promising approach for patients with multifocal seizure onset or eloquent cortex involvement. However, the clinical impact of combination surgery remains poorly characterized. The aim of this study was to characterize the clinical rationale and surgical decision-making used across multiple high-volume epilepsy centers performing combination surgeries, and to evaluate the seizure outcomes and safety profile associated with this approach. METHODS: This retrospective study included patients with drug-resistant epilepsy who underwent RNS implantation in combination with resection or LITT at 9 epilepsy centers and had ≥ 1 year of follow-up. Demographic, clinical, surgical, and seizure outcome data were collected. The primary outcome was seizure reduction at 1 year. Secondary outcomes included the Clinical Global Impression and adverse events. RESULTS: Overall, 73 patients (40 male, mean age 34 years) with a mean epilepsy duration of 21 years were included in this analysis. The most common etiology was unknown (37%), followed by cortical malformation (16%). Most patients experienced focal impaired consciousness (FIC, 78%) and focal to bilateral tonic-clonic (FBTC, 70%) seizures. Prior resection was performed in 23%. Combination procedures were performed on the same day in 89% of patients. RNS implantation was concurrent with resection in 92% and with LITT in 8.2% of patients. Neocortical and mesial temporal regions accounted for 61% of resection/ablation targets. More than two-thirds of RNS leads were subdural strips, most commonly in the left hemisphere (73%). Indications for the combined approach included eloquent cortex involvement (67%) and multifocal seizure onset (33%) or both (9.6%). At 1 year, mean seizure reductions were 53% for focal impaired, 69% for FIC, and 67% for FBTC seizures. Overall, 48% of patients had at least a 6-month period of seizure freedom, and 4 patients had no seizures after surgery. Significant global clinical improvement (much or very much improved) was observed in 79% of patients. Three patients experienced infection, and 1 patient died due to causes unrelated to surgical treatment (sudden unexpected death in epilepsy). CONCLUSIONS: Combined RNS with resection or ablation might provide meaningful seizure control in complex drug-resistant epilepsy with acceptable safety profiles. These findings describe current practice and support further investigation of hybrid surgical strategies in patients with challenging seizure networks as a potential treatment strategy.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Lopez Ramos CG, Raslan AM, Rao VR, et al. Combining responsive neurostimulation with resection or ablation for treatment of epilepsy: a multicenter experience. J Neurosurg. 2026. PMID: 42887034. doi:10.3171/2026.5.JNS252911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。